Patents by Inventor Daniel J. Poon

Daniel J. Poon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted benz-azoles and methods of their use as inhibitors of RAF kinase
    Patent number: 8614330
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: December 24, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Leonard Sung
  • Substituted benzimidazoles and methods of their use
    Patent number: 8592459
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: November 26, 2013
    Assignee: Novartis AG
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Pyrimidine derivatives used as PI-3 kinase inhibitors
    Patent number: 8563549
    Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: October 22, 2013
    Assignee: Novartis AG
    Inventors: Matthew Burger, Zhi-Jie Ni, Sabina Pecchi, Gordana Ataliah, Sarah Bartulis, Kelly Frazier, Aaron Smith, Joelle Verhagen, Yanchen Zhang, Allan Wagman, Simon Ng, Keith Pfister, Daniel J. Poon, Alicia Louie, Teresa Pick, Paul Barsanti, Edwin Iwanowicz, Wendy Fantl, Thomas Hendrickson, Mark Knapp, Hanne Meritt, Charles Voliva, Marion Wiesmann, Xiahua Xin
  • SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
    Publication number: 20130224195
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: April 3, 2013
    Publication date: August 29, 2013
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • Substituted benzazoles and methods of their use as inhibitors of RAF Kinase
    Patent number: 8415382
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: April 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
    Publication number: 20120288501
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 15, 2012
    Applicant: Novartis Vaccines and Diagnostics, Inc. formerly known as Chiron Corporation
    Inventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung
  • Substituted benzazoles and methods of their use as inhibitors of raf kinase
    Patent number: 8299108
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: October 30, 2012
    Assignee: Novartis AG
    Inventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung
  • SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION
    Publication number: 20100256375
    Abstract: Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R1, R2, R3, R4, a, b, and c are defined herein
    Type: Application
    Filed: June 18, 2010
    Publication date: October 7, 2010
    Inventors: Martin Dimitroff, Bridget R. Miller, Brady S. Stillwell, David A. Siesel, Tyson Swiftney, Brian Diaz, Danlin Gu, Jonathan P. van Dyck, David Ryckman, Daniel J. Poon, Teresa E. Pick
  • PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS
    Publication number: 20100249126
    Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
    Type: Application
    Filed: January 22, 2007
    Publication date: September 30, 2010
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.
    Inventors: Matthew Burger, Zhi-Jie Ni, Sabina Pecchi, Gordana Atallah, Sarah Bartulis, Kelly Frazier, Aaron Smith, Joelle Verhagen, Yanchen Zhang, Allan Wagman, Simon Ng, Keith Pfister, Daniel J. Poon, Alicia Louie, Teresa Pick, Paul Barsanti, Edwin Iwanowicz, Wendy Fantl, Thomas Hendrickson, Mark Knapp, Hanne Meritt, Charles Voliva, Marion Wiesmann, Xiahua Xin
  • SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE
    Publication number: 20100234394
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 16, 2010
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
    Publication number: 20100196368
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: March 12, 2010
    Publication date: August 5, 2010
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Leonard Sung
  • Substituted benzimidazoles and methods of preparation
    Patent number: 7767820
    Abstract: Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R1, R2, R3, R4, a, b, and c are defined herein
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: August 3, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martin Dimitroff, Bridget R. Miller, Brady S. Stillwell, David A. Siesel, Tyson Swiftney, Brian Diaz, Danlin Gu, Jonathan P. Van Dyck, David Ryckman, Daniel J. Poon, Teresa E. Pick
  • Substituted benzimidazoles and methods of their use
    Patent number: 7732465
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: June 8, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    Patent number: 7728010
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: June 1, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J Poon, Savithri Ramurthy, Paul A Renhowe, Cynthia M Shafer, Sharadha Subramanian, Leonard Sung
  • Substituted benzimidazoles and methods of their use
    Publication number: 20090170904
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: December 5, 2008
    Publication date: July 2, 2009
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase
    Publication number: 20090035309
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: September 5, 2008
    Publication date: February 5, 2009
    Inventors: Abran COSTALES, Teresa HANSEN, Barry H. LEVINE, Christopher McBRIDE, Daniel J. POON, Savithri RAMURTHY, Paul A. RENHOWE, Cynthia M. SHAFER, Sharadha SUBRAMANIAN, Joelle VERHAGEN
  • Substituted benzimidazoles and methods of their use
    Patent number: 7482367
    Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: January 27, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
  • Substituted benzimidazoles and methods of preparation
    Publication number: 20080287682
    Abstract: Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R1, R2, R3, R4, a, b, and c are defined herein
    Type: Application
    Filed: May 5, 2008
    Publication date: November 20, 2008
    Inventors: Martin Dimitroff, Bridget R. Miller, Brady S. Stillwell, David A. Siesel, Tyson Swiftney, Brian Diaz, Danlin Gu, Jonathan P. van Dyck, David Ryckman, Daniel J. Poon, Teresa E. Pick
  • Substituted benzazoles and methods of their use as inhibitors of Raf kinase
    Patent number: 7423150
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: September 9, 2008
    Assignee: Novartis AG
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    Patent number: 7071216
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: July 4, 2006
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Savithri Ramurthy, Payman Amiri, Barry Haskell Levine, Daniel J. Poon, Sharadha Subramanian, Leonard Sung, Wendy Fantl, Teresa Hansen, Christopher McBride, Cynthia M. Shafer